BioPharma Dive – AI / Data

How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup

Published

2 weeks ago

on

Cohen says he looked at around two dozen companies since Acorda wound down. Oryon Cell Therapies, with its funding, data and “autologous” approach, stood out amongst the crowd.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version